WASHINGTON — A Food and Drug Administration advisory committee on Friday urged approval of a new drug for the treatment of chronic hepatitis B, the drug manufacturer said.
Don't miss these Health stories
More women opting for preventive mastectomy - but should they be?
- Larry Page's damaged vocal cords: Treatment comes with trade-offs
- Report questioning salt guidelines riles heart experts
- CDC: 2012 was deadliest year for West Nile in US
- What stresses moms most? Themselves, survey says
- More women opting for preventive mastectomy - but should they be?
The drug, entecavir, is taken orally and is designed to work by preventing the virus that causes the illness from reproducing.
The advisory committee recommended approval despite studies indicating an increase in cancer in mice administered the drug. In studies in humans the main side effects were headache, diarrhea, fatigue and upset stomach, the company reported.
The chronic form of hepatitis B can damage permanently the liver and lead to cirrhosis and liver cancer.
Entecavir, made by Bristol-Myers Squibb, will be sold under the trade name Baraclude if it gets FDA approval. The agency isn’t required to follow the recommendations of its advisory committees, though it generally does so.
Current treatment options for chronic hepatitis include the drugs interferon, given by injection, and two drugs administered orally, lamivudine and adefovir dipivoxil.
The Hepatitis B Foundation estimates that 1.2 million Americans have hepatitis B and another 100,000 are infected annually.
© 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.